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1. introduction 
Fabry’s disease in an X-linked disorder characterized 
by the abnormal accumulation of a neutral glycolipid, 
trihexosylceramide (galactosylgalactosylglucosylcer- 
amide) [ 11. The clinical manifestations include a 
vascular rash of the skin, febrile crises, and severe pain 
in the extremities. The deficient enzyme is the one 
which cleaves the glycosidic bond between the terminal 
and pre-terminal galactose residues of trihexosylcer- 
amide [2]. A deficiency of ol-galactosidase (EC 3.2.1. 
22), assayed with the synthetic substrates p-nitrophenyl 
a-galactopyranoside and 4-methylumbelliferyl 
a-galactopyranoside, has been found in leukocytes [3] 
and skin tibroblasts [4, 51 of patients. Heterozygotes 
have two clonal populations of fibroblasts, one with 
a-galactosidase activity similar to controls and the 
other with activity in the range of patients [4]. 
The specificity of the assay for a-galactosidase, ba- 
sed on the use of synthetic substrates, has been quest- 
ioned [6,7] because it was thought that the terminal 
glycosidic bond of the natural substrate had a 
p-anomeric configuration, but recent studies have 
shown the terminal galactose of trihexosylceramide 
to be an ol-anomer [8-l 11. However, the enzymatic 
assay based on the use of synthetic substrates might 
measure the activity of more than one cr-galactosidase 
and, indeed, two forms of the enzyme have been par- 
tially purified and characterized from human kidney 
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[ 121. They can be differentiated as a thermolabile 
form (A) and a thermostable form (B). The A form 
has a more acidic pI (4.6) than the B form (pl 4.9) 
and migrates faster towards the anode on Cellogel 
electrophoresis. Only the A form is deficient in most 
patients affected with Fabry’s disease, as shown by 
this and other studies [ 13-151. However, in one of 
the patients presented here, both forms of a-galacto- 
sidase and a residual activity towards the natural sub- 
strate, trihexosylceramide, were present. This finding 
can be explained by heterogeneity of the mutations 
affecting the structural locus coding for o-galactosidase, 
which has recently been shown by means of somatic 
cell hybrids to be X-linked in man [ 161. 
2. Materials and methods 
2,l. Cell culture 
Five unrelated patients affected with Fabry’s disease 
were studied (table l), two of whom (no. 4 and no. 5) 
were recently described as clinical variants of the 
disease since they had no skin lesions [7]. Fibroblast 
cultures were initiated from skin biopsies of patients 
and controls and cells were harvested and sonicated 
as previously described [4]. 
2.2. Assay of cu-galactosidase 
The enzymatic activity of a-galactosidase was assay- 
ed in an incubation mixture containing 625 nmoles of 
4-methylumbelliferyl cr-D-galactopyranoside (Koch- 
Light), 10 pmoles of acetate buffer at pH 5.0, and 10 
~1 of cell sonicate, incubated in a volume of 65 ~1 for 
30 min at 37”. The reaction was stopped by adding 
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Table 1 
Properties of or-galactosidase from patients and controls as 
assayed with the synthetic substrate, 4-methylumbelliferyl 
+galactoside. 
Fibroblast line 
1) M.M. 
2) J.L. 
3) F.L. 
4) A.H. 
5) R.C. 
Control average + SD. 
(Number of controls) 
Specific activity 
(units/mg protein) 
4.1 
7.1 
8.8 
3.3 
10.1 
29.2 f 5.3 
(5) 
K, value 
(mM) 
26.8 
16.5 
15.8 
21.6 
5.8 
2.1 It 0.7 
(6) 
0.1 M Tris to a final volume of 5 ml. Appropriate 
dilutions were read in a Turner fluorometer equipped 
with 110.811 primary filters and 110.816 and 831 
secondary filters and standardized with 4-methyl- 
umbelliferone. Protein content was measured in dupli- 
cates [ 171, and the specific activity was expressed as 
nmoles of substrate hydrolyzed/mg of protein/hr at 
37” and pH 5.0. The enzymatic activity was linear 
with protein concentration. 
2.3. Assay of @zlactosidase 
The incubation mixture containing 20 pmoles of 
acetate buffer (pH 4.0) 3 gmoles of NaCI, 0.1 pmoles 
of 4-methylumbelliferyl fl-D-galactopyranoside (Pierce) 
and 10 ~1 of cell sonicate in a final volume of 0.25 ml 
was incubated for 15 min at 37’. The reaction was 
stopped by adding 0.1 M Tris to a volume of 10 ml or 
more, and readings were taken as described above. 
2.4. Putification and radioactive labelling of trihexo- 
sylceramide 
The trihexosylceramide was isolated from an acetone 
powder of 1 kg of human kidney by the method of 
Martensson [ 181 and further purified by preparative 
thin-layer chromatography on silica gel G in: i) &IO- 
roform-methanol-NH40H (60:30:8), to separate 
glycolipids from residual phospholipids; and ii) chlo- 
roform-methanol-Hz 0 (30:30:4), to separate tri- 
hexosylceramide from globoside. 
The purified trihexosylceramide migrated as a single 
spot on both thin-layer chromatography systems des- 
cribed above, and was free of contaminating phospho- 
lipids as determined by the molybdenum test [19]. 
The molar ratio of galactose to glucose liberated by 
enzymatic hydrolysis [lo] agreed with that expected 
(2: l), and 92% of the expected total sugar residues 
were recovered after acid hydrolysis [20]. 
About 20 mg of this purified trihexosylceramide 
were labeled in the terminal galactose residue by 
oxidation with galactose oxidase (12.5 units, 
Worthington) followed by reduction of 25 &i of 
3H-NaBH4 (524 mCi/mmole, Amersham) [20]. After 
dilution with 20 mg of unlabeled trihexosylceramide, 
95% of the radioactivity migrated as the marker on 
thin-layer chromatography. The specific activity of 
this 3H-trihexosylceramide was 28 /Ki/pmole. In or- 
der to show that the only labeled sugar residue in the 
molecule was the terminal galactose, the [3H]trihexo- 
sylceramide was incubated with a-galactosidase puri- 
fled from fig latex and with /l-galactosidase purified 
from jack bean [lo]. The former glycosidase cleaves 
the terminal bond of trihexosylceramide (Gal $$ Gal), 
while the latter cleaves the preterminal bond 
(Gal $e Glc). Aliquots of 10 pmole of [3H]trihexo- 
sylceramide were incubated, respectively, with fig 
a-galactosidase alone or sequentially with both fig 
a-galactosidase and jack bean /3-galactosidase [lo]. No 
further radioactivity was liberated when the [ 3 H]tri- 
hexosylceramide treated with a-galactosidase was 
subjected to a second incubation with fl-galactosidase. 
Following the same procedure, a second batch of 
[3H]trihexosylceramide with high specific activity 
(240 pCi/pmole) was prepared. 
2.5 Assay of trihexosylceramide cu-galactosidase 
The activity of trihexosylceramide cu-galactosidase 
was assayed with a modification of the procedure des- 
cribed by Brady et al. [2]. The reaction mixture (0.1 
ml) contained 20 nmoles of radioactive substrate, sus- 
pended in 10 ~1 of a solution of 2% sodium cholate 
(w/v), 10 pmoles of potassium acetate (pH 5.0), 1 mg 
of human serum albumin and enzyme. After 4 hr of 
incubation at 37”, the reaction was stopped by adding 
in this order: 0.9 ml of cold HzO, 0.1 ml of 10% 
bovine serum albumin and 0.1 ml of 100% tricliloro- 
acetic acid. After mixing and centrifugation, the pellet 
was resuspended in 1 ml of 10% cold trichloroacetic 
acid and treated as before. To the combined superna- 
tants 1 ml of anhydrous ether was added and, after 
mixing and centrifugation, an aliquot of the lower 
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phase was counted in a scintillation vial with Bray’s 
solution. At least 92% of the galactose was recovered 
at the end of this procedure. 
2 6. Partial purification of cr-galactosidase 
The enzyme from tibroblast cultures was partially 
purified by ethanol precipitation. Cells from 10 to 20 
petris (6.5 cm diameter) were harvested with a rubber 
policeman after one month in culture (see Results), 
and the pellet was resuspended in 2 to 4 ml of 0.01 M 
acetate buffer, pH 4.5, containing 0.4% Na deoxy- 
cholate and sonicated. After centrifugation for 15 min 
at 25,OOOg, 95% ethanol was added to the supernatant 
with stirring at -10” to a final cont. of 61%. After 
centrifugation the pellet was resuspended in 0.5 ml of 
1 mM citrate-phosphate buffer, pH 7.0, and spun 
again. More than 70% of the initial activity was recov- 
ered in the clear supernatant with a 4-fold purification 
of a-galactosidase. 
3. Results 
3.1. Deficiency of a-galactosidase A 
The fibroblasts from all five patients showed a par- 
tial deficiency of cr-galactosidase and their specific 
activities ranged between 10% and 30% of the mean 
of the controls (table 1). Some physicochemical prop- 
erties of the enzyme from tibroblasts of patients and 
controls were compared. They had similar pH depen- 
dence in the range tested (pH 3.0-7.0) and only one 
peak of optimum activity between pH 4.4 and 4.8. 
The Km values of cr-galactosidase for the synthetic 
substrate, as figured from a Lineweaver-Burk plot, in 
the first four patients were significantly higher than 
in controls, whereas for the fifth patient this value 
was similar to that of the controls (table 1). 
The rate of heat inactivation of the a-galactosidase 
from the first four patients was clearly slower than 
that of the wild-type enzyme for the first 20 min at 
51” (fig. l), whereas the enzyme from the fifth patient, 
who also showed a lower Km value, had during the 
same period a greater thermolability rate than that of 
the remaining patients. This kind of difference seemed 
to indicate at first a structural difference between the 
a-galactosidase of the first four patients and of the 
controls [21], but the study of the heat inactivation 
for a longer period, up to 1 hr, showed that the rate 
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Fig. 1. Heat inactivation of or-galactosidase in fibroblasts from 
patients and controls. Aliquots of enzyme were preincubated 
at 5 1” for the time indicated and assayed with the synthetic 
substrate as described under Methods, in a final volume of 0.1 
ml. Number 1 corresponds to patient No. 1 of table 1 and is 
representative of the group of patients l-4. Number 5 corre- 
sponds to patient no. 5 of table 1, and number 6 is a repre- 
sentative control out of a total of 13 controls. 
of inactivation of the enzyme from controls and from 
the fifth patient was represented by two lines with dif- 
ferent slopes (fig. 1). This suggests the presence in these 
individuals of a mixture of two enzymes, one being 
thermolabile (A) and the other thermostable (B), 
whereas in the majority of the patients (nos. l-4) 
only cr-galactosidase B is apparent. 
3.2 Increase of enzymatic activity with time in culture 
The specific activity of a-galactosidase in fibroblasts 
from patients or controls did not change with time in 
culture if cells were subcultured at intervals of 3-4 
days. However, the specific activity of a-galactosidase 
increased with time in culture if the same lines derived 
from a control and a patient were maintained in a 
strationary phase of growth, that is, in the same petri 
without subculturing (fig. 2). The specific activity of 
a-galactosidase from the mutant line increased about 
lo-fold in a period of 30 days, and that from the con- 
trol line about 4-fold. The specific activity of 
/I-galactosidase, on the other hand, increased 5-fold in 
both strains. 
No variation of the K,,, value and thermolability 
properties of a-galactosidase concomitant with this 
increase in activity was observed. 
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Fig. 2. Increase of specific activity of CY- and p-galactosidase with time in culture. Fabry’s hemizygote is a fibroblast line from patient 
no. 1 of table 1. 
3.3. Deficiency of trihexosylceramide cu-galactosidase 
The enzyme from various tibroblast lines, partially 
purified by ethanol precipitation (see Methods) was 
assayed with the [3H]trihexosylceramide (specific ac- 
tivity 28 yCi/pmole). The cu-galactosidase from a con- 
trol fibroblast line hydrolyzed 1.5 nmoles of [ 3H]tri- 
hexosylceramide/mg protein/hr. The enzyme from 
patient no. 5 showed one-tenth of the specific activity 
of the control (0.147 nmoles/mg protein/hr) while no 
detectable activity was measured in two mutant 
iibroblast lines (patients nos. 1 and 4). In order to 
increase the sensitivity of the assay, [3H]trihexosyl- 
ceramide with high specific activity (240 &i//lmoie, 
see Methods) was used. It was found that the fibroblast 
line from patient no. 1 hydrolyzed between 6 and 9 
pmoles of this substrate/mg protein/hr, whereas two 
control lines had an activity of 2.6 and 1.6 nmoles/mg 
protein/hr, respectively. 
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4. Discussion 
The data presented here constitute biochemical and 
genetic evidence that cu-galactosidase A is deficient in 
Fabry’s disease. The first four patients showed a resi- 
dual a-galactosidase activity which amounted to lo- 
30% of the total activity found in controls, as assayed 
with the synthetic substrate 4-methylumbelliferyl 
cY-galactoside. This residual cw-galactosidase activity 
was thermostable, like the thermostable component 
(or a-galactosidase B) found also in the fibroblasts of 
the controls. The high Km value found in these four 
patients was similar to that described for cu-galactosidase 
B [ 131. In contrast, the fifth patient, besides the B form 
of a-galactosidase, also had the A form, as shown by 
the heat inactivation and by the low Km value, similar 
to that of the controls. Even from a clinical point of 
view, this patient was unusual since he lacked the skin 
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lesions and had only mild manifestations of his disease 
[7]. When the activity of trihexosylceramide cu-galacto- 
sidase was assayed in this patient, about one-tenth of 
the activity of the controls was found, whereas in pa- 
tient no. 1 (quite representative of the group of the 
first four patients) this enzymatic assay showed an 
activity of about l/350 of that found in the controls. 
The demonstration of this low but significant level of 
activity excludes the possibility that the enzymatic 
deficiency of Fabry’s disease is caused by a deletion 
mutation. The occurrence of a milder degree of en- 
zymatic deficiency in the fifth patient is indicative of 
genetic heterogeneity. Although genetic heterogeneity 
can be best explained by the presence of different 
mutations affecting the same structural locus coding 
for a-galactosidase, other explanations are possible. 
It has been proposed, for instance, that the X-linked 
deficiency of a-galactosidase A in Fabry’s disease is 
caused by a mutation of an X-linked regulatory locus 
which, in turn, would cause a deficiency of o-galacto- 
sidase A [ 131. Although there is no need to postulate 
the existence of an X-linked regulatory locus, the 
structural locus for a-galactosidase being X-linked 
itself [ 161, the occurrence of regulatory mutations in 
Fabry’s disease the B form, which is normally sialid- 
another explanation has been put forward. Since it 
seems that the A form of this enzyme can be converted 
into the B form by treatment with sialidase [ 141, it has 
proposed that the B form is a precursor of A and that 
in Fabrys’s disease the B form, which is normally sialid- 
ated by a sialyl-transferase, is so structurally altered as 
to become a poor acceptor of sialic residues [ 141. This 
hypothesis would explain the deficiency of o-galacto- 
sidase in Fabry’s disease as a result of point mutation 
of the X-linked locus specifying a-galactosidase. 
The presence of sialic acid residues has been shown 
to be important for the in viuo stability of different 
sialoglycoproteins [22], and this could justify the 
presence of two cu-galactosidases, one being the native 
or precursor form and the other final or complete en- 
zyme. However, no definitive conclusion should be 
drawn until the purification and characterization 
of both forms of a-galactosidase are completed. 
On the basis of the available evidence it is not even 
possible to decide whether trihexosylceramide is the 
substrate for only the A form or for both the A and B 
forms. The data presented here would agree with either 
alternative. 
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